非小细胞肺癌EGFR-TKIs耐药机制的研究进展

近年来，随着医学分子生物学的飞速发展，分子靶向治疗理念的提出使肿瘤治疗进入一个新阶段。在对非小细胞肺癌（NSCLC）的分子学研究中，表皮生长因子受体（EGFR）突变成为目前研究最热门的分子靶点，针对这一靶点的表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）如吉非替尼、厄洛替尼等，已经广泛应用于临床治疗。然而，有一部分患者对EGFR-TKIs的治疗并不敏感或对其产生耐药性，影响了EGFR-TKIs的临床疗效。本文就EGFR-TKIs的耐药机制以及解除耐药的相应策略进行综述。

Research progress of the mechanisms on the drug-resistance of EGFR-TKIs in non-small cell lung cancer

In recent years, medical molecular biology has being rapidly developed and a new era of antitumor treatment is coming with the novel concept for molecular-targeted strategies. Epidemal growth factor receptor tyrosine kinase inhibitors （EGFR- TKIs）, such as gefitinib and erlotinib, have being widely used in clinic. However, the efficiency is limited because of the drug resistance or poor sensitivity in some populations with non-small cell lung cancer（NSCLC） during therapy. The review briefly summarizes the pro- gress on mechanisms of EGFR-TKIs resistance and strategies currently being employed to overcome resistance.